Put companies on watchlist
MEDIQON Group AG
ISIN: DE0006618309
WKN: 661830
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MEDIQON Group AG · ISIN: DE0006618309 · EQS - adhoc news (50 News)
Country: Germany · Primary market: Germany · EQS NID: 1302161
14 March 2022 07:03PM

MEDIQON Group AG: NGC Nachfolgekapital GmbH, a subsidiary of MEDIQON Group AG, entered into a transaction agreement in relation to its subsidiary vetera GmbH


DGAP-Ad-hoc: MEDIQON Group AG / Key word(s): Miscellaneous
MEDIQON Group AG: NGC Nachfolgekapital GmbH, a subsidiary of MEDIQON Group AG, entered into a transaction agreement in relation to its subsidiary vetera GmbH

14-March-2022 / 19:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


NGC Nachfolgekapital GmbH, a subsidiary of MEDIQON Group AG, entered into a transaction agreement in relation to its subsidiary vetera GmbH

Today, Nordhealth A/S and NGC Nachfolgekapital GmbH, an 80% subsidiary of MEDIQON Group AG agreed that vetera GmbH, an 80% subsidiary of NGC Nachfolgekapital GmbH will become part of the Portfolio of Practice Management Software Companies of Nordhealth A/S.

The consideration will be structured as a mix of cash and shares in Nordhealth A/S.

Vetera is a software and service provider for veterinarians in the DACH region and was acquired by NGC Nachfolgekapital GmbH in June 2019.

With the transaction, NGC Nachfolgekapital GmbH realizes a significant uplift in value compared to the original purchase price paid in 2019. The effect on the Base Value per end of 2021 as calculated by MEDIQON Group AG amounts to c. EUR 0,27 per share. Under German GAAP ("HGB"), there will be no direct impact on the financial statements of MEDIQON Group AG as the parent company. At closing, the shareholder loans granted by MEDIQON Group AG for the acquisition will be fully repaid.

The transaction is expected to close in Q2 2022, subject to satisfaction of customary closing conditions.


14-March-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MEDIQON Group AG
Herzog-Adolph-Strasse 2
61462 Königstein im Taunus
Germany
Phone: +49 (0) 6174-9687040
Fax: +49 (0) 6174-9687043
E-mail: ir@mediqon-group.de
Internet: www.mediqon-group.de
ISIN: DE0006618309, DE000A254TL0
WKN: 661830, A254TL
Listed: Regulated Unofficial Market in Berlin, Frankfurt (Basic Board), Stuttgart
EQS News ID: 1302161

 
End of Announcement DGAP News Service

1302161  14-March-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1302161&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MEDIQON Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.